JP2023544409A - 皮膚筋炎を治療する方法 - Google Patents

皮膚筋炎を治療する方法 Download PDF

Info

Publication number
JP2023544409A
JP2023544409A JP2023520448A JP2023520448A JP2023544409A JP 2023544409 A JP2023544409 A JP 2023544409A JP 2023520448 A JP2023520448 A JP 2023520448A JP 2023520448 A JP2023520448 A JP 2023520448A JP 2023544409 A JP2023544409 A JP 2023544409A
Authority
JP
Japan
Prior art keywords
dermatomyositis
fusion protein
muscle
administered
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023520448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544409A5 (enExample
Inventor
ポール ピー． タンブリーニ，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023544409A publication Critical patent/JP2023544409A/ja
Publication of JP2023544409A5 publication Critical patent/JP2023544409A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2023520448A 2020-10-05 2021-10-05 皮膚筋炎を治療する方法 Pending JP2023544409A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063087577P 2020-10-05 2020-10-05
US63/087,577 2020-10-05
PCT/US2021/053540 WO2022076388A1 (en) 2020-10-05 2021-10-05 Methods of treating dermatomyositis

Publications (2)

Publication Number Publication Date
JP2023544409A true JP2023544409A (ja) 2023-10-23
JP2023544409A5 JP2023544409A5 (enExample) 2024-10-15

Family

ID=81126239

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520448A Pending JP2023544409A (ja) 2020-10-05 2021-10-05 皮膚筋炎を治療する方法

Country Status (10)

Country Link
US (1) US20230357442A1 (enExample)
EP (1) EP4225372A4 (enExample)
JP (1) JP2023544409A (enExample)
KR (1) KR20230084210A (enExample)
CN (1) CN116472065A (enExample)
AU (1) AU2021358027A1 (enExample)
CA (1) CA3172994A1 (enExample)
IL (1) IL301713A (enExample)
MX (1) MX2023004034A (enExample)
WO (1) WO2022076388A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250030978A (ko) * 2022-06-03 2025-03-05 알렉시온 파마슈티칼스, 인코포레이티드 중증 근무력증의 치료를 위한 융합 폴리펩티드의 투여량 및 투여
CN116313071B (zh) * 2023-01-16 2023-09-08 南方医科大学南方医院 一种预测初诊皮肌炎患者发生快速进展型间质性肺病的风险模型的构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014360A1 (en) * 2017-07-11 2019-01-17 Alexion Pharmaceuticals, Inc. POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2794359A (en) * 1953-09-22 1957-06-04 Lyman Gun Sight Corp Automatic primer feed device
KR102071212B1 (ko) * 2010-04-21 2020-01-30 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
KR102149028B1 (ko) * 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
US10531135B2 (en) * 2016-01-04 2020-01-07 Telefonaktiebolaget Lm Ericsson (Publ) Network recording apparatus
MX2021011507A (es) * 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
AU2022283254A1 (en) * 2021-05-25 2023-11-30 Alexion Pharmaceuticals, Inc. Kidney active fusion proteins and methods of treatment using the same
WO2023023220A1 (en) * 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014360A1 (en) * 2017-07-11 2019-01-17 Alexion Pharmaceuticals, Inc. POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"National Library of Medicine [online]、Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis", 公開日：2008.03.04, [検索日：2025.07.22], JPN6025033900, ISSN: 0005791446 *

Also Published As

Publication number Publication date
WO2022076388A1 (en) 2022-04-14
MX2023004034A (es) 2023-06-09
US20230357442A1 (en) 2023-11-09
EP4225372A4 (en) 2024-11-06
CA3172994A1 (en) 2022-04-14
KR20230084210A (ko) 2023-06-12
AU2021358027A1 (en) 2023-05-11
CN116472065A (zh) 2023-07-21
EP4225372A1 (en) 2023-08-16
IL301713A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
JP2023090876A (ja) 高濃度抗ｃ５抗体製剤
JP2023517236A5 (enExample)
CN115925919A (zh) 改进的血清白蛋白结合免疫球蛋白可变结构域
JP2003523764A5 (enExample)
US12534525B2 (en) Aqueous pharmaceutical composition of an anti-IL17A antibody and use thereof
EP2318437A2 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
CN104684929A (zh) 治疗血管疾病及其并发症
KR20240130134A (ko) 갑상선 눈 질환의 치료를 위한 조성물 및 방법
KR20240141213A (ko) 갑상선 눈 질환의 치료를 위한 조성물 및 방법
KR20180084045A (ko) 비형 간염 표면 항원에 대한 항체 및 그의 용도
IL293367A (en) Pharmaceutical formulations and dosage regimens for antibodies to factor xi/xia
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
US20220025031A1 (en) Methods for treating spinal cord injury and pain
WO2025128839A1 (en) Methods for the treatment of thyroid eye disease with anti igf-1r antagonistic antibodies
CN116472065A (zh) 治疗皮肌炎的方法
KR20230093499A (ko) 인간 대상체에서 타우를 감소시키는 방법
JP2023534779A (ja) 抗セラミド抗体
AU2021390125A1 (en) Pharmaceutical composition comprising anti-connective tissue growth factor antibody
JP2022530063A (ja) 抗体製剤
US20190119394A1 (en) Compositions and methods for treating pancreatitis and pain with death receptor agonists
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders
WO2025081130A1 (en) Use of anti-asc antibody in the treating of ocular disorders
TW202519258A (zh) 使用抗群落刺激因子１受體抗體治療慢性移植物抗宿主病之方法
JP2025084861A (ja) 再発型の多発性硬化症を治療するための方法
CN120000779A (zh) 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260206